SEC filingsOct 12, 2026 to Oct 19, 2026: insiders reported 840 purchases and sales across 212 companies.840 insider purchases and sales in 7 daysSee the filings →
HornScout

Company profile

ABOS

Acumen Pharmaceuticals, Inc.
NASDAQHealth Care

Latest close: 1.69 USD · Oct 16, 2026 · 1 year · split-adjusted

On the price, the facts of the public record■Insider buy□Insider sell◇Significant stake declared (13D)●Results filed
With an account, also○dividends▲splits◌next earningswith an account

End-of-day prices provided by Twelve Data · One close per session; the series does not update during the trading day.

Latest on record

The most recent facts, as filed.

Up to three of the most recent, checkable facts already loaded on this page, each linked to its source.

  1. Sep 16, 2026Material event · 8-KFiled by the company itself.Open the filing ↗
  2. Aug 12, 2026Quarterly report · 10-QFiled by the company itself.Open the filing ↗
  3. Aug 12, 2026Material event · 8-KFiled by the company itself.Open the filing ↗

In numbers

What this profile holds, counted.

Closes · 1 year250
SEC filings on record3349 flagged findings
Reported transactions (Form 4)80since Jun 10, 2024
Corporate events (8-K)11since Jan 3, 2022

What the record says

Description, identity and filings, each with its source.

Every block cites its source. The colour of a finding marks its category — which document, who filed it — not how much it matters.

SEC topics

Regulatory history

Topics detected in its SEC reports, with the original excerpt.

Each topic is assigned by a classifier over the full filing; the excerpts show where it was detected and are not always enough to verify it. Open the filing to read it in full.

  • 2026-03-26capital return (buybacks/dividends)recentOpen filing ↗
    “…except, in the case of any director of officer, where the director or officer breached his or her duty of loyalty, failed to act…”
  • 2026-03-26share offering or dilution eventrecentOpen filing ↗
    “…to use the net proceeds from the Private Placement to primarily support our EBD program, including ongoing preclinical development…”
    +1 more passage from the same document
    • “…Amended and Restated Certificate of Incorporation is 310,000,000 , with 10,000,000 shares designated as preferred stock with a…”
  • 2026-03-26listing compliance noticerecentOpen filing ↗
    “…our common stock when you wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to…”
    +1 more passage from the same document
    • “…determination to pay dividends in the future will be at the discretion of our board of directors. Accordingly, investors must rely…”
  • 2026-03-26capital return (buybacks/dividends)recentOpen filing ↗
    “…218,774 Purchases of property and equipment ( 88 ) ( 16 ) Net cash provided by investing activities 133,933 48,027 Cash flows…”
    +1 more passage from the same document
    • “…and listing standards applicable to the Company. The Company’s insider trading policy is included as an exhibit to this Annual…”

Original excerpts from SEC filings, untranslated. Not advice and not a prediction.

SEC record

SEC dossier

What this company has filed with the SEC, in plain language.

The 25 most recent filings (of 334)

Everything filed

Every SEC filing, newest first, with what it is. Below, each type with its own explanation.

  • Sep 16, 268-K ↗Current report · Communication to the market
  • Aug 12, 2610-Q ↗Quarterly report
  • Aug 12, 268-K ↗Current report · Results · Communication to the market
  • Jun 17, 26Form 144 ↗Notice of proposed sale
  • Jun 17, 26Form 4 ↗Insider transaction
  • Jun 16, 26Form 144 ↗Notice of proposed sale
  • Jun 16, 268-K ↗Current report · Communication to the market · Other events
  • Jun 15, 26Form 144 ↗Notice of proposed sale
  • Jun 10, 26Form 4 ↗Insider transaction
  • Jun 9, 26Form 144 ↗Notice of proposed sale
  • Insider transaction · 8 Form 4 filingsshow all 8hide
  • Jun 3, 268-K ↗Current report · Shareholder vote results
  • May 12, 2610-Q ↗Quarterly report
  • May 12, 268-K ↗Current report · Results · Communication to the market
  • Apr 23, 26DEFA14A ↗Shareholder meeting and votes
  • Apr 23, 26DEF 14A ↗Shareholder meeting and votes
  • Apr 7, 26SCHEDULE 13G ↗Passive stake · James B. Murray Jr. · 5.0% · event on Apr 4, 25
  • Apr 1, 26424B3 ↗Securities offering

334 filings on record, the oldest from May 10, 21.

Listing the 25 most recent filings of the 334 on record.

8-Ks, explained

Structure6Governance5
  • Mar 16, 26StructureEntered a material agreement+3 more in the same filing8-K 1.01 ↗
  • Nov 10, 25GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Jul 15, 25StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Feb 1, 24GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
  • Structure3 material agreements entered2023show all 3hide
    • Nov 9, 23StructureEntered a material agreement8-K 1.01 ↗
    • Jul 20, 23StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
    • Apr 27, 23StructureEntered a material agreement+2 more in the same filing8-K 1.01 ↗
  • Governance3 senior executive changes2022 – 2023show all 3hide
    • Jan 4, 23GovernanceA senior executive left or was appointed8-K 5.02 ↗
    • Aug 15, 22GovernanceA senior executive left or was appointed+2 more in the same filing8-K 5.02 ↗
    • Jan 3, 22GovernanceA senior executive left or was appointed8-K 5.02 ↗

Corporate events are tracked from 2004-08-23, when the SEC renumbered 8-K items. Earlier filings use an incompatible numbering and are not classified here.

Ownership and control

Schedule 13D: stake and stated purpose

Filed by holders above 5% of a share class who cannot use the short form. It includes the investor's stated purpose: read it before assuming they seek influence.

  • RA Capital Management, L.P.29.5%Mar 13, 26SCHEDULE 13D/A ↗4 co-filers on this document — the figure is the largest single stake, not their sum. · 1 earlier filing

Schedule 13G: short-form filing

The short form, for holders who meet specific requirements: institutional investors, passive investors without a control purpose, or exempt investors. Asset managers and index funds usually file it.

  • Sands Capital Alternatives, LLC5.6%Jun 30, 25SCHEDULE 13G/A ↗5 co-filers on this document — the figure is the largest single stake, not their sum.
  • James B. Murray Jr.5.0%Apr 4, 25SCHEDULE 13G ↗
  • Franklin Resources, Inc.3.8%Sep 30, 25SCHEDULE 13G/A ↗3 co-filers on this document — the figure is the largest single stake, not their sum.

Structured 13D/G data starts 2023-12, when the SEC moved these filings to a machine-readable format. Earlier filings exist but are not parsed here.

SEC record

Insider transactions

Buys and sells reported by officers, directors and major shareholders on SEC Form 4.

Buys and sells

  • Jun 17, 26Sell$30KDerrell Porter↗
  • Jun 16, 26Sell$30KDerrell Porter↗
  • Jun 15, 26Sell$15KDerrell Porter↗
  • Jun 9, 26Sell$14KNathan B Fountain↗
  • Mar 6, 26Sell$7KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Feb 27, 26Sell$28KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Jan 28, 26Sell$8KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Jan 26, 26Sell$45KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Jan 23, 26Sell$11KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Jan 22, 26Sell$850Russell BartonChief Operating Officer↗
  • Jan 22, 26Sell$5KDaniel Joseph OConnellChief Executive Officer↗
  • Jan 22, 26Sell$3KMatt ZugaCFO & Chief Business Officer↗

There are 10 more transactions in this stretch.

Stock compensation, tax and giftsshow the 18 other transactionshide

Stock compensation, tax withholding, option exercises and gifts. They are listed separately and are not included in the purchase and sale totals. The type describes the transaction, not the filer's intent.

  • Jun 17, 26Compensation$14KDerrell Porter↗
  • Jun 15, 26Compensation$7KDerrell Porter↗
  • Jun 3, 26Compensationamount n/aKimberlee C Drapkin↗
  • Jun 3, 26Compensationamount n/aGeorge Golumbeski↗
  • Jun 3, 26Compensationamount n/aJohn A Stalfort III↗
  • Jun 3, 26Compensationamount n/aNathan B Fountain↗
  • Mar 16, 26Compensation$20.0MRA CAPITAL MANAGEMENT, L.P.↗
  • Mar 6, 26Compensation$4KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Feb 27, 26Compensation$17KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Jan 28, 26Compensation$5KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Jan 26, 26Compensation$28KDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Jan 20, 26Compensationamount n/aDaniel Joseph OConnellChief Executive Officer↗
  • Jan 16, 26Compensationamount n/aJames J. DohertyPresident and CDO↗
  • Jan 16, 26Compensationamount n/aAmy SchacterleChief Regulatory Officer↗
  • Jan 16, 26Compensationamount n/aRussell BartonChief Operating Officer↗
  • Jan 16, 26Compensationamount n/aEric SiemersChief Medical Officer↗
  • Jan 16, 26Compensationamount n/aDerek M MeisnerChief Legal Officer & Corp Sec↗
  • Jan 16, 26Compensationamount n/aMatt ZugaCFO & Chief Business Officer↗

The full record holds 108 transactions and goes back to Dec 29, 22.

Its sector and its market

Acumen Pharmaceuticals, Inc. among Health Care companies

The profile shows what is on record. Context and Radar place the company among those of its sector and region.

With an account you also get

  • The four engines — growth, trend, risk and context — each with its word and its score.
  • The risk band and the sector phase.
  • The company's fundamentals and accounts.
  • Watchlist: your list of companies, with the «since you follow it» figure.

The research continues

The profile tells the story. The market sets the scene.

From Acumen Pharmaceuticals, Inc., the path continues in the other areas. Each one is shown with its own example, named in its step.

  1. Place it in its market

    Seven layers of its region's market — rates, credit, stress, liquidity, regime, breadth and sectors — with historical precedents. Public example: Apple and ASML.

    See how Context works →
  2. See what deserves a closer look

    Every morning Radar screens the covered companies through a lens and explains why each candidate made the list. Public example: the lists from Aug 11, 2026.

    See how Radar works →
  3. Keep the why

    Follow Acumen Pharmaceuticals, Inc. in the Watchlist and review what changed since you added it: context, notices and filings. Written theses are coming soon. Public example: Apple.

    See an example review →

Coverage

What sits behind this page.

Where each figure comes from and how far it reaches.

Prices
End-of-day closes provided by Twelve Data. One close per session; not real time. Closes adjusted for splits.
Series quality
250 clean closes in the period.
SEC records
334 documents on file, from May 10, 2021 to Sep 16, 2026.
Company description
No description available.
This page
Generated on Oct 18, 2026; refreshed through the day.

Start at your own pace

Explore first. Go deeper with access.

Every company's public profile is open. The full reading — context, Radar, watchlist — is inside, in an invitation-only beta.

Compare plans →
  • No account

    This profile for every company we cover: closing prices with the record's facts on the curve, the SEC file in plain language, insider trades included, and links to its sector and exchange.

  • Pro

    What matters today, with its reason, is free with an account. Pro adds, in the profile, each company's notices and their explanation and the analysis of its insiders; in Radar, all the lenses, which notice each candidate carries, filters by notice type and «no dilution», and the cycle cohort filter; and in Watchlist, more companies and notice changes with their reason.

  • Pro+

    Adds the Lab: test a hypothesis on comparable cohorts before reusing it; and bring your lenses to Radar.

Are the prices real time?

No. It is one close per session, from the provider and with the date shown on the profile; it does not update during the trading day.

Which SEC documents appear here?

Those filed with the SEC by the company, its insiders and its major shareholders, within our coverage: periodic reports (10-K, 10-Q, 20-F), material events (8-K), proposed sale notices (Form 144), insider transactions (Form 4) and stakes above 5% (13D/13G). Each links to the original on EDGAR.

Why does a European company show no SEC records?

It depends on the company: some European issuers file a 20-F or 6-K with the SEC and others don't. The profile shows whatever is on record; when there is nothing, it says so rather than guessing why. Europe does not yet have a common filing archive like EDGAR in the United States. The EU will open its own, ESAP, in July 2027 (managers' transactions arrive in January 2028), and we plan to add it once it is available.

Before forming a view on a company,
read what is on record.

One close per session. The record in plain language. Its sector and its market one link away. Your judgment when deciding.

Access by invitation while the beta lasts. Not advice: the profile shows what is on record; it does not recommend.